Type 2 Diabetes: In the Lancet Phase 2 trial, retatrutide reduced HbA1c by up to 2.16 percentage points at the highest doses, accompanied by a robust weight reduction (~17% at 36 weeks)
Do not change the dose or convert between milligrams, millilitres and syringe units without professional guidance
This study was supported by the So Paulo Research Foundation (FAPESP
Each batch is handled according to internal quality standards designed to support consistency, verification, and controlled research workflows
This personalized data empowers you to make informed decisions about injection logistics, potential dosing strategies, and whether your current site-rotation plan aligns with your unique genetic profile
After excluding non-ocular studies and duplicates, 188 articles were included following a full-text review